KERX Financial Facts

Total operating expenses: 35.65M
Operating loss: -35.4M
See Full Income Statement

Total current liabilities: 28.13M
Interest receivable: 151K
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 3/12/15 *Est. EPS Growth Rate -100.0% *Last Qtr.
Average EPS % Beat Rate -38.9% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +0.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A Details
11/2/11 Q311 -$0.15-$0.12 -$0.03N/AN/A N/A Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A Details